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Abstract
Background: Asthma and obesity are public health problems with increasing prevalence worldwide. Clinical and
epidemiologic studies have demonstrated that obese asthmatics have worse clinical control and health related
quality of life (HRQL) despite an optimized medical treatment. Bariatric surgery is successful to weight-loss and
improves asthma control; however, the benefits of nonsurgical interventions remain unknown.
Methods/Design: This is a randomized controlled trial with 2-arms parallel. Fifty-five moderate or severe asthmatics
with grade II obesity (BMI≥ 35 kg/m2) under optimized medication will be randomly assigned into either weight-loss
program + sham (WL + S group) or weight-loss program + exercise (WL + E group). The weight loss program will be
the same for both groups including nutrition and psychological therapies (every 15 days, total of 6 sessions, 60 min
each). Exercise program will include aerobic and resistance muscle training while sham treatment will include a
breathing and stretching program (both programs twice a week, 3 months, 60 min each session). The primary
outcome variable will be asthma clinical control. Secondary outcomes include HRQL, levels of depression and anxiety,
lung function, daily life physical activity, body composition, maximal aerobic capacity, strength muscle and sleep
disorders. Potential mechanism (changes in lung mechanical and airway/systemic inflammation) will also be examined
to explain the benefits in both groups.
Discussion: This study will bring a significant contribution to the literature evaluating the effects of exercise
conditioning in a weight loss intervention in obese asthmatics as well as will evaluate possible involved mechanisms.
Trial registration: NCT02188940
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Background
Asthma is a chronic respiratory disease characterized by
episodes of reversible airway obstruction, chronic airway
inflammation and airway hyperresponsiveness. Its symp-
toms include wheezing, shortness of breath, chest tight-
ness and cough, which may resolve either spontaneously
or with the administration of an appropriate treatment
[1]. Asthma affects approximately 300 million people
worldwide and is expected to affect an additional 100
million people by 2025 [1, 2]. The dramatic increase in
the prevalence of asthma over the past few decades has
occurred in conjunction with an increase in the preva-
lence of obesity [3, 4], a finding suggestive of a possible
relationship between the two conditions. Obesity is char-
acterized by excess fat accumulation in the body as a re-
sult of a complex interaction among genetics, dietary
caloric intake and energy expenditure and is often diag-
nosed in adults with a BMI ≥ 30.0 kg/m2 [5]. Obesity
also affects a large number of individuals, as more than
200 million men and nearly 300 million women are
obese. The prevalence of obesity is highest in WHO
Regions of America (27 % of obesity) and lowest in the
WHO Regions for South East Asia (5 % of obesity) [6].
Many cross-sectional epidemiologic studies have demon-
strated a relationship between asthma and obesity [7–9].
Obesity is a major risk factor for asthma, as over-
weight and obese subjects are 38 % and 92 % more
likely to develop asthma, respectively, than patients
with normal weights [10]. Additionally, obesity results
in the development of a difficult-to-control asthma
phenotype in which patients experience worse clinical
control, poorer quality of life, reduced lung function,
poor responses to corticosteroids and more psycho-
social symptoms [11–14]. As obesity is a risk factor
for the development of asthma, Global Initiative for
asthma (GINA) 2014 [1] recommends weight loss for
all obese asthmatics.
Some interventions have been considered for weight
loss in obese asthmatic patients and bariatric surgery has
been suggested as a means of improving asthma control,
lung function and decreased medication usage [15, 16].
However, the most recent guidelines pertaining to the
management of obesity recommend utilizing a compre-
hensive approach to weight-loss intervention focused on
diet, physical activity and behaviour self-management as
a first-line therapy [17].
A recent Cochrane review found only 4 randomized
controlled trials (RCTs) pertaining to weight loss in the
setting of asthma [18] via nonsurgical intervention. Two
trials used meal replacement with a very low calorie diet
[19, 20], and Dias-Junior et al. [21] combined a low cal-
orie diet with anti-obesity drugs (orlistat and subtra-
mine). Each of these studies observed positive effects
following weight loss. The study by Scott et al. [22] was
the only to include physical activity as an adjuvant treat-
ment; the authors observed that the patients who par-
ticipated in physical activity did not experience
additional benefits in terms of weight loss and im-
provements in clinical control, although this finding
may have overlooked the levels of physical activity in
which these patients participated at baseline. There-
fore, the Cochrane review study did not find any
studies using a comprehensive approach to lifestyle
intervention focused on diet, physical activity and be-
haviour self-management as recommended by the
most recently published guidelines [17].
Recent evidence suggests that improving physical fit-
ness among patients with asthma is important because it
improves airway hyperreactivity [23], psychosocial fac-
tors [24], and health related quality of life [25], and also
reduces the need for corticoid administration [23, 26].
Moreover, recent studies have also demonstrated the
anti-inflammatory effects of exercise training in pa-
tients with asthma [27, 28]; these results are consist-
ent with those of studies utilizing animal asthma
models [29–31]. Additionally, improvements in physical
fitness also effect the immune system in obese subjects by
decreasing the activity of pro-inflammatory mediators
[Interleukin (IL-6), monocyte chemotactic protein-1
(MCP-1), C-reactive protein (CRP), IL-8 and tumour
necrosis factor (TNF-α)] and increasing the levels of anti-
inflammatory markers and mediators (adiponectin and IL-
10) [32–34]. Therefore, exercise not only plays a role in
lifestyle interventions intended to facilitate weight loss in
asthma but is also an intervention in and of itself.
As previously discussed, asthma and obesity are clin-
ical conditions characterized by chronic inflammation;
the effects of exercise have been evaluated in the setting
of each condition but not in the setting of both diseases
together. Our hypothesis is that exercise training ampli-
fies weight loss and exerts both anti-inflammatory and
immunoregulatory effects, resulting in improved clinical
control and quality of life, as well as improved psycho-
social symptoms and sleep disorders among obese asth-
matic patients. The objective is to assess the effects of
exercise training in a weight-loss program on asthma
control, quality of life and psychosocial symptoms in
obese patients with stable asthma.
Methods
Study design
This is a prospective and randomized open-label con-
trolled trial with 2 arms and blinded assessments. Both
groups will receive similar educational and weight loss
interventions (composed of both nutritional and psycho-
logical therapies), but only one group will perform exer-
cise training. The study design is depicted in Fig. 1.
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Study setting
The patients will be recruited from an outpatient
asthma clinic at a University hospital. The Hospital
Research Ethics Committee of the University of Sao
Paulo approved the study, (07137512.9.0000.0068) and
all patients provided written informed consent before
participating. This study is registered on Clinical-
Trials.gov as NCT02188940.
Eligibility criteria
Patients between 30 and 60 years of age with class II
obesity (BMI ≥ 35 kg/m2) and either moderate or severe
persistent asthma according to the GINA criteria [1] will
be eligible to participate. The subjects will have to be
under medical treatment for at least 6 months and to
have clinically stable disease (no hospitalizations, emer-
gency care or medication changes for at least 30 days).
The patients should will also be physically inactive as de-
fined by the American College of Sports Medicine’s
(ACSM) guidelines (less than 60 min of structured or
planned physical activity per week) within the last
6 months [35]. The exclusion criteria included the fol-
lowing: the presence of another pulmonary disease, ei-
ther cardiovascular or musculoskeletal diseases that may
interfere with the patient’s evaluations or impair exercise
training, active cancer, a weight change greater than 5 %
within the last 6 months, taking anti-obesity drugs
within the past 3 months, a history of bariatric surgery,
either uncontrolled hypertension or diabetes, and the
use of continuous positive airway pressure. Patients who
are participating in another research protocol or are un-
able to understand our questionnaire, as well as smokers
or ex-smokers (≥10 pack-years), pregnant women or
breast feeding women, will also be excluded. The inter-
ventions will be performed between 2 medical appoint-
ments in order to avoid medication changes.
Experimental design
The patients will be assessed before and after the in-
terventions on 3 non-consecutive days. On day 1, an-
thropometric indexes, body composition, asthma
symptoms and peripheral muscle strength will be
Fig. 1 Study flow chart. After being included in the study, the patients will be evaluated during 3 non-consecutives visits. Each of the groups will
receive the same education program and will participate in the same weight loss program* (composed of nutrition and psychological therapy);
however, only one of the groups will participate in exercise training, as the remaining group will perform a sham intervention (breathing and
stretching exercises). The groups will performed 24 intervention session, after which they will undergo a second evaluation utilizing the same
tests as the baseline evaluation
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assessed. On day 2, asthma clinical control will be
assessed via an asthma control questionnaire (ACQ),
an asthma quality of life questionnaire (AQLQ), and a
hospital anxiety depression scale (HADS); sleep dis-
order history, lung function and exercise capacity will
be also assessed. On day 3, the exhaled fraction of ni-
tric oxide (FeNO), daily life physical activity and sys-
temic inflammation will be measured. Following these
baseline evaluations, all eligible patients will receive a 6-h
educational program and will be subsequently randomly
assigned into the following 2 groups: either a weight loss
program (including nutritional and psychological therapy)
with a sham treatment (WL + S group), or the same
weight loss program with exercise (WL + E group). All
patients will complete 24 treatment sessions, after which
they will be reevaluated.
Allocation, randomization and blinding
The eligible patients will be randomly allocated to their
respective intervention group. The randomization sched-
ule will be computer-generated and carried out by an in-
vestigator blinded to the recruitment, evaluation and
treatment of the participants. Each patient’s allocation
will be concealed using sequentially numbered, sealed
and placed in opaque envelopes. The researcher that will
provide the treatments who will be not involved in the
data collection, will open the envelopes and will inform
the group allocated to each participant. The participants
will be informed if they would receive 1 out 2 different
interventions to facilitate weight loss. Due to the nature
of the interventions, it will not be possible to blind the
physiotherapist that will provide the exercise training
and the breathing and stretching programs; however, the
nutritional and psychological interventions, as well as
the assessments of each of the variables and the data
analysis, will be given in a blinded manner.
Interventions
Educational program
Both groups will complete an educational program con-
sisting of 4 classes held twice a week before the inter-
ventions, each lasting 90 min. The 2 first classes will be
based on an education videotape, the ABC of asthma, as
well as presentations and group discussions pertaining
to asthma pathophysiology, medication and peak flow
meter skills, self-monitoring techniques, environmental
control and avoidance strategies in accordance with pre-
vious studies [24, 36] and asthma guidelines [1]. During
the 2 last classes, the patients will also receive informa-
tion and educational materials regarding current inter-
national physical activity recommendations and the
benefits thereof [35].
Nutritional intervention
A nutritionist will conduct the nutritional program with
visits every 2 weeks during the 3 month intervention
period, for a total of 6 sessions of 60 min each for both
groups. The patients will be advised to follow a hypoca-
loric diet in which the calorie intake of each patient will
be estimated by multiplying adjusted body weight (at a
BMI of 25 kg/m2) by 20 calories [37]. Food consumption
will be evaluated using a 24-h food record, and all cal-
oric intake, macronutrients and micronutrients will be
quantified using NutWin® software (recommended diet-
ary allowances based on a food pyramid) [38]. The pa-
tients will complete the food dairy at the beginning (1st
session), the middle (3rd session) and the end (6th ses-
sion) of the sessions. During each session, the nutrition-
ist will measure and record the patients’ weights, discuss
the importance of maintaining a balanced diet, and pro-
mote appropriate daily food intake and make each pa-
tient aware of the responsibility one bears in controlling
one’s weight (Table 1).
Behavioural therapy
A psychologist will provide the therapy every 2 weeks
for a total of 6 sessions of 60 min each for both groups.
Table 1 Nutritional program
No. session Activities
1 Presentation of the group and the nutritional program
The measurement and recording of body weights,
concepts of BMI/obesity range
A balanced food pyramid and how to complete the
24 hour food intake dairy
2 The measurement and recording of body weight
Individualized calorie goals with dietary suggestions
Daily food routine and portion sizes
3 The measurement and recording of body weight
The role of carbohydrates, proteins and fats in a diet
Choices of low-energy and nutrient-dense meals and snacks
4 The measurement and recording of body weight
The role of vitamins and minerals
The ideal amount of nutrient intake to lose weight and
stay healthy
5 The measurement and recording of body weight
Healthy food preparation techniques and proposals
for healthy meals
The risk of diabetes and hypertension associated with
obesity (comorbidities)
6 The measurement and recording of body weight
“Virtual restaurant” and how to read a food nutrition labels
Careful selection of restaurants and the finalization
of the nutrition program
BMI body mass index, No. number of session. The nutritional program will be
performed every 15 days over 3 months for a total of 6 sessions of 60 min each
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Group sessions using behavioural techniques (such as
self-management, motivational strategies, positive
reinforcement and relapse prevention) will be provided
in order to improve patient adherence to the weight loss
program [39]. The interventions will be based on the
Transtheoretical model, which recognizes that behaviour
changes are dynamic processes that move through stages
and reinforces change via goal setting, skill development
and self-control [39]. The psychologist will discuss sev-
eral issues related to behaviour changes, using relaxation
techniques, internal experiences and patient self-
reporting (Table 2). The nutritional and psychological
programs will be similar for both groups but they will be
performed separately for each group to avoid that
patients from distinctive groups meet themselves.
Exercise training program
The exercise training program will include aerobic and
resistance exercises supervised by a physiotherapist and
will be offered to only one of the groups (WL + E group).
The program will be performed twice a week for
3 months for a total of 24 sessions of 60 min each. In
order to avoid joint discomfort and improve patient ad-
herence to the exercise program, aerobic training will be
performed on both a treadmill (Jog 700, Technogym,
Italy) and either a bike (Bike 700, Technogym, Italy) or
an elliptical (Syncro 700, Technogym, Italy) machine.
The intensity of the aerobic training will be based on
peak oxygen consumption (peak VO2) and monitored
using each patient’s target heart rate (THR). Exercise in-
tensity will begin with a THR of 50 to 60 % of peak VO2
and will be increased by 5 % every 2 weeks based on
symptoms and perceived exertion, using the modified
Borg scales for leg discomfort and dyspnea [40], reaching
a maximum of 75 % of peak VO2 [41]. Each patient will
receive an accelerometer in order to record daily num-
bers of steps during the 1st, 6th and 12th weeks to en-
courage an increased physical activity level. In order to
complete the amount of weekly physical activity recom-
mended by the international guidelines [35], the patients
will be also advised to walk at least twice a week for
30 min and to complete a daily physical activity record.
Both heart rate and the modified Borg scale [40] will be
assessed during each session before exercise, every
10 min during exercise and after exercise. Peak expira-
tory flow (PEF) will be measured before each session,
and inhaled salbutamol (200 μg) will be recommended if
values < 70 % were observed. The safety of the exercise
training will be monitored by quantifying PEF, blood
pressure and asthma symptoms before and after each
exercise session as previously described [28].
The aerobic training will be interspersed with resist-
ance training for the upper and lower limbs, targeting
the following major muscle groups: chest, deltoid, quad-
riceps and hamstrings. Patients will begin the resistance
training by performing 2 sets of 10 repetitions with an
intensity of 50 % to 70 % of the one-maximal resistance
test (1-RM) [42]; progression will take place first in the
number of repetitions (until 2 sets of 15 repetitions are
reached). When each patient reaches 15 repetitions, the
load will be increased from 1 to 3 kg for the exercises
for the upper limbs and 5 to 10 kg for the lower limbs,
depending on the muscle being exercised and the
patient’s tolerance level.
Sham treatment
The breathing and stretching exercise programs will be
completed only by the WL + S group; the sessions will
be performed twice a week for 12 weeks and will be su-
pervised by a physiotherapist. The breathing and exercise
programs will be performed as a sham treatment as previ-
ously described [24, 28], without an intensity progression.
The program will be based on Yoga’s pranayama breathing
exercises, including kapalabhati, uddhiyana and agnisara,
as previously described [43]. Briefly, every exercise will be
completed in 3 sets with 2 min of exercise intercalated
with 60 s of rest for a total of 30 min each session. The
stretching program will consist of exercises for the follow-
ing major muscle groups: trapezius, pectoralis, gluteus,
Table 2 Psychological program
No. session Activities
1 Presentation of the participants
Explanation of the psychological program
Assessment of patients’ expectations regarding weight loss
2 Breathing relaxation techniques to control anxiety
Experiences concerning weight loss (successes and relapses)
Identification of the reasons for and the onset of obesity
in each patient
3 Emotional versus physiological hunger (learning to listen
to the body)
Feeding behaviour and pleasure from food
The identification of personal barriers to weight loss
and potential solutions to overcoming these barriers
4 Self-efficacy (dynamic group using drawings)
A review of self-monitoring records and progress
Realistic goal setting and action plans
5 Dynamic group called “time for self-care”
Responsibility regarding food choices
How to deal with relapses during the program
6 Dynamic group activities using the mirror to increase
each patient’s morale
A review of self-monitoring records and progress
Finalization of the program
No. number of session. The psychological program will be completed every
15 days over 3 months for a total of 6 sessions of 60 min each
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hamstrings, quadriceps femur, paraspinal, latissimus dorsi
and pubic adductors. The exercises will be completed in 2
sets of 10 s each for a total of 30 min each session. The
safety of these exercises will be monitored in the same
way as the exercise training. The breathing and stretching
exercises will be included as a sham intervention in the
WL+ S group in order to minimize the differences in the
numbers of hospital visits and the amounts of patient at-
tention between the two groups, not to induce respiratory
breathing training benefits.
Outcomes
Primary outcome
The primary outcome of this study will be the absolute
change in the asthma control questionnaire (ACQ) post
intervention between the groups following the interven-
tion. The ACQ is both a reliable and validated method of
measuring the impairment in asthma control [44, 45] and
includes specific parameters regarding both daytime and
nocturnal asthma symptoms, activity limitations, dyspnea,
wheezing and rescue bronchodilator use within the last
week (a short-acting B2-agonist) [45]. An additional ques-
tion assessing forced expiratory volume in 1 s (FEV1) (%
predicted, pre-bronchodilator) is completed by the re-
searcher. The ACQ contains 7 items rated on a 7-point
scale (0 = without limitation, 6 =maximum limitation),
with a higher score indicating worse control. The ACQ
has been validated for Brazilian Portuguese [46]. Previous
studies have demonstrated that scores lower than 0.75
points are associated with good asthma control, whereas
scores greater than 1.5 points are indicative of poorly con-
trolled asthma [44]. A change of at least 0.5 points on the
ACQ is regarded as clinically significant [47].
Secondary outcomes
The asthma quality of life questionnaire (AQLQ)
The asthma quality of life questionnaire [48, 49] consists
of 32 items rated on a 7-point scale (1 = great deal, 7 =
not at all) divided into the following 4 domains: activity
limitations, symptoms, emotional function and environ-
mental stimuli. The AQLQ has been translated and vali-
dated for Portuguese patients [50]. A higher AQLQ
score indicates a better quality of life; clinically effective
treatment resulted in a 0.5 point increase in the score
following the intervention [51].
Levels of anxiety and depression
Symptoms of anxiety and depression will be evaluated
using the Hospital Anxiety and Depression Scale (HADS)
[52], which consists of 14 items divided into 2 subscales (7
for anxiety and 7 for depression). Each item is scored from
0 to 3, with a maximum score of 21 points for each sub-
scale. A score greater than 9 in each subscale suggests a
diagnosis of either anxiety and/or depression [53].
Asthma symptoms and exacerbations
Asthma symptoms and exacerbations will be evaluated
using a symptom diary as previously reported [24]. The
asthma diary includes questions about episodes and
symptoms (coughing, wheezing, shortness of breath,
nocturnal awakenings and the number of puffs of as-
needed β2-agonist). Days free of asthma symptoms will
be considered when the patient did not report any symp-
toms; these days will be totalled on a monthly basis.
Asthma exacerbations will be defined as an increase in
symptoms associated with at least one of the following cri-
teria: the use of ≥ 4 puffs of rescue medication per 24 h
during a 48-h period, a need of systemic corticosteroids,
an unscheduled medical appointment, and either a visit to
an emergency room or a hospitalization.
Sleep disorders
The Berlin questionnaire will be used to estimate the
risk (low to high) of obstructive sleep apnoea syndrome
(OSA) [54]. The questionnaire consists of 10 items, di-
vided into the following 3 domains: snoring and wit-
nessed apnoeas (5 items), daytime sleepiness (4 items)
and high blood pressure/obesity (1 item). Each category
is classified as positive if the score is ≥ 2 points. Add-
itionally, if the patients have at least 2 positive categor-
ies, they will be considered high risk for developing
OSA. The Berlin questionnaire has been translated and
validated for Portuguese [55]. The ActiSleep monitor
(Pensacola, FL, USA) will be also used to objectively
evaluate the sleep of patients. The participants will be
instructed to use the monitor over a period of 7 con-
secutive nights on their non-dominant wrist. During this
monitoring period, the participants will keep a sleep
diary in which they will record the times at which they
fall asleep, as well as when they awake each morning.
We will analyze the following parameters: the total
amount of sleep, sleep latency, the number and duration
of awakenings and sleep efficiency [56].
Daily life physical activity (DLPA)
The accelerometer “ActiGraph GT3X” (ActiGraph,
Pensacola, FL, USA) will quantify objectively the abso-
lute change in DLPA. This device uses a solid-state tri-
axial accelerometer to collect motion data on 3 axes
(vertical and horizontals right-left and front-back) and
measures and records time-varying accelerations [57].
The counts obtained in a given time period are linearly
related to the intensity of the physical activity monitored
during this period [58]. All units will be initialized via a
computer interface to collect data in 60-s epochs in the
3 axes using specific software (ActiLife 6.9.5 Firmware
version). Each participant will be instructed to use the
accelerometer over a period of 7 consecutive days, with
the device positioned securely on the patient’s hip (non-
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dominant side) using an elastic belt. During the study
period using the accelerometer, the patients will keep a
diary in which they will record bathing times and the
times at which they begin to fall asleep and awake each
morning. The accelerometer will record automatically
each patient’s energy expenditure (Kcal), metabolic
equivalent unit (MET), step counts, sedentary behaviour,
and cut off points, as well as time (%) when sedentary or
engaged in light, moderate or vigorous activity, and time
(%) in the standing, sitting and supine positions [59].
Body composition
Body composition will be analyzed via an octopolar tactile
bioelectrical impedance analysis (InBody720 - Biospace,
Seoul, South Korea). An electrode system separately mea-
sures the impedance of the subject’s trunk, arms, and legs
at 6 different frequencies (at 1, 5, 50, 250, 500 and
1000 kHz) and evaluates body segment. The equipment
will analyze the percentages of body fat mass, soft lean
mass, fat free mass, skeletal muscle mass and visceral fat
area (cm2). The equipment has a high test-pretest reliabil-
ity and accuracy [60]. The patients will be advised to fast
for at least 4 h, refrain from physical activity for 8 h prior
to testing, and avoid taking diuretics at least 24 h before
testing [61].
Anthropometric indexes
The patients’ heights, weights (Filizola®, Brazil), waist cir-
cumferences, hip circumferences and waist to hip ratios
(WHRs) will be measured using a standardized protocol
[62, 63]. BMIs will be obtained by dividing patients’
weights in kilograms by their heights in meters squared
(kg/m2) [64].
Cardiopulmonary exercise test (CPET)
The cardiopulmonary exercise test will be performed
using an electrical cycle ergometer (Corival, Lode B.V.;
Medical Technology, The Netherlands) linked to a digital
equipped with an exercise evaluation system (CardioO2
System; Medical Graphics Corporation), in accordance
with American Thoracic Society/American College of
chest physicians (ATS/ACCP) guidelines [65]. Oxygen sat-
uration (SpO2), as measured via pulse oximetry (Onyx,
model 9500; Nonin, Plymouth, MN), and electrocardiog-
raphy (Welch Allyn CardioPerfect, Inc., NY) will be moni-
tored continuously during the tests. The following
variables will be recorded breath-by-breath during rest,
during exercise and following testing: work rate (WR),
VO2, minute ventilation (VE), carbon dioxide production
(VCO2), respiratory exchange rate (RER) and heart rate
(HR). Additionally, blood pressure, the Borg score for leg
discomfort and dyspnea, and inspiratory capacity (IC) will
be measured at rest and every 2 min during testing until
the end of testing [40]. The patients will perform a ramp-
symptom-limited CPET consisting of 2 min of rest, 2 min
of warm-up (unloaded pedalling) and an incremental work
period (an increase from 10 to 20 W/min, taking into ac-
count the patient’s level of daily activity [66]. The pre-
dicted CPET values will be obtained from the Brazilian
population [67].
Peripheral muscle strength
The maximal strength tests will be evaluated via a one
repetition maximum test (1-RM) test in order to deter-
mine the load used at the beginning of resistance train-
ing [42]. The 1-RM test is defined as the maximum
weight that an individual can lift in a single repetition
and will be performed as previously described [42].
Briefly, the participants (1) will be familiarized with the
equipment using minimal resistance; (2) will perform a
3-min warm-up period; (3) will complete 8 repetitions at
approximately 50 % of the estimated 1-RM, followed by
3 repetitions of approximately 70 % of the estimated 1-
RM; and (4) will complete single repetitions (maximum
5 trials) utilizing progressively heavier weights in order
to meet the 1-RM. The recovery period among series
should not be less than 1 min or more than 5 min. The
1-RM test will involve the following movements: exten-
sion of the arms, inclined bench press and seated leg
press and extension of the feet.
Evaluating possible mechanisms
Pulmonary function
Spirometry and lung volume measurements will be per-
formed using a calibrated whole-body plethysmograph
(Medical Graphics Corporation - MGC, St Paul, Mm,
USA) according to both American Thoracic Society and
European Respiratory Society (ATS/ERS) recommenda-
tions [68, 69]. Data related to IC, total lung capacity
(TLC), expiratory reserve volume (ERV), functional re-
sidual capacity (FRC) and residual volume (RV) will be
expressed both as totals and as percentages of predicted
values [70]. A spirometer will be used to measure FEV1,
forced vital capacity (FVC), forced expiratory flow 25–75
(FEF 25-75 %), peak expiratory flow (PEF) and maximal
voluntary ventilation (MVV). Spirometry evaluations will
be conducted before and after the administration of 200
mcg of inhaled salbutamol. Increases of either 12 % or
200 ml in FEV1 will be categorized as positive responses
to bronchodilator therapy [68]. The predicted values will
be provided by Pereira et al. [71].
Airway inflammation
Airway inflammation will be quantified using the ex-
haled fraction of nitric oxide (FeNO), using a portable
analyser (NIOX MINO®; Aerocrine AB, Solna, Sweden),
in accordance with ATS/ERS guidelines [72]. The pa-
tients will be asked to exhale fully while seated before
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inhaling through a NIOX filter until they will reach their
total lung capacity, and immediately will exhale at a con-
stant flow rate of 50 ml/s using a visual feedback system.
The average levels of at least 3 acceptable measurements
will be used. The patients will be instructed to avoid eat-
ing foods containing nitrate and caffeine and to avoid
smoking and exercise 24 h before testing, as well as to
refrain from ingesting either food or water for at least
2 h before testing. NO collection will be performed by
the same professional at the same time of day in order
to avoid changes in patients’ circadian rhythms. A cut off
point of 25 parts per billion (ppb) will be used to either
confirm or exclude a diagnosis of eosinophilic airway
inflammation [72].
Systemic inflammation
Patients’ inflammatory systemic profiles will be assessed
using blood-based markers. Venous blood samples will
be collected following at least 8 h of overnight fasting,
and the patients will be advised to avoid exercise, alco-
holic and caffeinated beverages 24 h before testing. The
cytometric bead array method (BD Biosciences, San Jose,
CA, USA) will be used to analyse the levels of IL-1, IL-2,
IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, TNF-α, vascu-
lar endothelial growth factor (VEGF), T-cell receptor
beta (TGF-β) and the chemokines MIG/CXCL9, IP-10/
CXCL10, IL-8/CXCL8, MCP-1/CCL2 and RANTES/
CCL5. Serum leptin, adiponectin, CRP (ELISA, MILLI-
PORE), cortisol (Siemens, Immulite 200) and vitamin D
(Ria-CT) levels will also be analyzed.
Data analysis
Sample size
Sample size was calculated based on the minimal im-
portant difference of 0.5 points between the groups [47]
on the ACQ questionnaire, with a standard deviation of
0.72 [73]. A sample size of 55 patients will be sufficient
to detect an effect size of 0.5 between the 2 arms for
80 % alpha 2-sided, assuming up to a 20 % loss to
follow-up.
Statistical analysis
An intention-to-threat analysis will be used to preserve
the effects of group allocation and provide an assess-
ment of the practical impact of the treatment [74], as
recommended by the CONSORT statement [75]. The
normality of continuous outcomes will be assessed via
the Kolmogorov-Smirnov test. Comparisons of the initial
and final data will be analyzed via a two-way repeated-
measures analysis of variance, and the categorical out-
comes, via the χ2 test. A partial correlation will be used
to test the effects of airway and systemic inflammation
as mediators. P values ≤ 0.05 will be considered statisti-
cally significant. The statistical analysis will be blinded
to the treatment allocation and will be performed using
specific software (SigmaStat 3.5, Systat Software Inc.).
Discussion
The association between asthma and obesity is an inter-
esting issue since the pathogenesis of asthma is altered
in obese asthmatics because they do not respond as well
to standard controller asthma therapy. The inclusion of
evidence-based weight loss strategies is recommended
by the GINA guidelines in spite of the lack of trials dem-
onstrating the intervention that is most effective in fa-
cilitating weight loss in obese asthmatics [18, 22].
The aim of the present study is to assess the effects of
exercise training in the setting of a weight loss interven-
tion on asthma control, quality of life and psychosocial
symptoms in obese asthmatics. It is important to under-
stand the role of exercise as part of a comprehensive
weight loss program in these patients, as well as to in-
vestigate possible mechanisms by which improvements
in physical fitness result in improvements in both clin-
ical and psychological variables. Additionally, sedentary
lifestyle and deconditioning both play key roles in the
development of respiratory symptoms in obese asthmatic
patients [76]. Furthermore, exercise is associated with im-
provements in airway hyperreactivity [23], psychosocial
factors [24], health related quality of life [25] and reduced
airway inflammation [28] among patients with asthma.
Additionally, exercise exerts positive effects on body
weight, cardiovascular disease risk factors and systemic in-
flammation among patients who are obese [32–34, 77].
Nevertheless, we are aware of only 2 studies investigat-
ing the effects of physical fitness among obese asthmatic
[22, 78]. Scott et al. [22] conducted a randomized trial
involving 46 overweight and obese adults with asthma
who were allocated to 3 distinct groups as follows: a
calorie-restricted diet group, an exercise training group
and a group receiving both interventions. Contrary to
our study hypothesis, the authors observed that exercise
training did not provide benefits in terms of weight loss
and improvements in clinical control on a calorie-
restricted diet program. It is important to note that they
did not observe improvements in physical activity levels
following their exercise training program and did not
perform evaluations pertaining to improvements in
physical fitness [22]. A possible explanation for their
findings is that their patients participated in a greater
amount of physical activity at baseline (61 % reported
participating in vigorous activity, and 24 % reported par-
ticipating in moderate physical activity). Furthermore,
they were already close to the 10.000 steps/day thresh-
old, suggesting they were physically active with respect
to international guidelines [79]. A recent trial [78] inves-
tigated the effects of an evidence-based comprehensive
weight loss intervention composed of diet, physical
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activity and behavioural therapy compared with standard
therapy in obese asthmatics. In spite of the inclusion of
a comprehensive weight loss intervention, the physical
activity program in this study included recommendation
to maintain a minimum of 150 min of physical activity
per week and not a supervised exercise protocol. The
patients in the intervention group experienced signifi-
cantly more weight loss compared with the control sub-
jects (respectively, −4.0 ± 0.8 kg vs. -2.1 ± 0.8 kg);
however, neither group observed any changes in either
ACQ or the numbers of asthma exacerbations.
The possible mechanisms underlying the improve-
ments in patients’ physical fitness may be related to
changes in lung mechanics and either systemic or airway
inflammation. We expect that the addition of exercise
training may have clinical benefits (reduced symptoms)
among obese asthmatic patients by decreasing asthma
allergic inflammation [28], as well as by amplifying
weight loss by increasing metabolic consumption, which
may subsequently decrease the low grade inflammation
commonly noted among patients who are obese [33, 34].
Weight loss exerts positive effects on lung function
among subjects with and without asthma [80] via im-
provements in chest wall compliance secondary to re-
duced mass loading effects caused by fat accumulation
in and around the chest wall. If our hypothesis is cor-
rect, reductions in body weight will improve ventilation
efficiency by improving chest wall compliance.
Improvements in physical fitness may reduce the levels
of pro-inflammatory mediators observed in subjects with
low-grade inflammation (high-sensitivity C-reactive pro-
tein, IL-6, TNF-α, MCP-1, IL-8, and leptin) [81–83] and
increase the levels of anti-inflammatory markers and
mediators (adiponectin and IL-10) [32–34]. We expect
that exercise training will facilitate decreases in the
levels of the systemic biomarkers that contribute to the
pathogenesis of asthma, as it has been demonstrated
previously that aerobic conditioning improves airway in-
flammation via reductions in FeNO levels among pa-
tients with asthma [28]. It has also been suggested that
exercise training modulates allergic inflammation by in-
creasing the expression of the anti-inflammatory cyto-
kines IL-10 and IL-1ra in an animal model of asthma
[84]. We hypothesized that there is a correlation be-
tween reduced FeNO, a marker of airway inflammation,
and increased levels of these anti-inflammatory cyto-
kines. Another possible effect of improved physical fit-
ness is an improved quality of sleep and a reduction in
psychological symptoms, as the prevalence of anxiety
and depression are significant in both patients with
asthma [85] and patients who are obese [85–87].
In conclusion, this study will bring a significant contri-
bution to the literature evaluating the effects of exercise
conditioning in a weight loss program; the results may
facilitate improvements in asthma control, quality of life
and psychosocial symptoms and help elucidate the pos-
sible mechanisms underlying the improvements in lung
function, as well as both airway and systemic inflamma-
tion, among obese asthmatic patients.
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